Assessment of doxorubicin toxicity using human cardiac organoids: A novel model for evaluating drug cardiotoxicity
- 23 October 2023
- journal article
- research article
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 386, 110777
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational OverviewAntioxidants & Redox Signaling, 2019
- Molecular mechanism of doxorubicin-induced cardiomyopathy – An updateEuropean Journal of Pharmacology, 2018
- The role of mitochondrial dysfunction in cardiovascular disease: a brief reviewAnnals of Medicine, 2017
- Toxicogenomic module associations with pathogenesis: a network-based approach to understanding drug toxicityThe Pharmacogenomics Journal, 2017
- New signal transduction paradigms in anthracycline-induced cardiotoxicityBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2016
- Serum biomarkers evaluation to predict chemotherapy-induced cardiotoxicity in breast cancer patientsTumor Biology, 2015
- Erratum: Cardiotoxicity of anticancer treatmentsNature Reviews Cardiology, 2015
- Plasma nuclear and mitochondrial DNA levels in acute myocardial infarction patientsCoronary Artery Disease, 2015
- Human Stem Cells for Modeling Heart Disease and for Drug DiscoveryScience Translational Medicine, 2014
- Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and TreatmentCurrent Cardiology Reviews, 2012